REVIEWS
Treatment of the primary tumor in breast cancer patients with synchronous metastases
D. Ali andR. Le Scodan
Ann Oncol
(2011)22(1):9-16first published online June 7, 2010 doi:10.1093/annonc/mdq301
Abstract
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
M. Joerger, B. Thürlimann, and J. Huober
Ann Oncol
(2011)22(1):17-23first published online June 20, 2010 doi:10.1093/annonc/mdq304
Abstract
Improving early breast cancer detection: focus on methylation
K. P. M. Suijkerbuijk, P. J. van Diest, and E. van der Wall
Ann Oncol
(2011)22(1):24-29first published online June 29, 2010 doi:10.1093/annonc/mdq305
Abstract
Update and new trends in antiemetic therapy: the continuing need for novel therapies
P. Feyer and K. Jordan
Ann Oncol
(2011)22(1):30-38first published online October 14, 2010 doi:10.1093/annonc/mdq600
Abstract
ORIGINAL ARTICLES
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
A. Poveda,
I. Vergote, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz, H. Hagberg, S. B. Kaye, N. Colombo, C. Lebedinsky, T. Parekh, J. Gómez, Y. C. Park, V. Alfaro, and B. J. Monk
Ann Oncol
(2011)22(1):39-48first published online July 19, 2010 doi:10.1093/annonc/mdq352
Abstract
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
A. Antón, A. Ruiz, A. Plazaola, L. Calvo, M. A. Seguí, A. Santaballa, M. Muñoz, P. Sánchez, A. Miguel, E. Carrasco, J. Lao, J. Camps, J. Alfaro, S. Antolín, and M. C. Cámara
Ann Oncol
(2011)22(1):74-79first published online July 5, 2010 doi:10.1093/annonc/mdq317
Abstract
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
C. Rochlitz, T. Ruhstaller, S. Lerch, C. Spirig, J. Huober, T. Suter, M. Bühlmann, M. Fehr, A. Schönenberger, R. von Moos, R. Winterhalder, D. Rauch, A. Müller, M. Mannhart-Harms, R. Herrmann, B. Cliffe, M. Mayer, K. Zaman, and on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Ann Oncol
(2011)22(1):80-85first published online July 1, 2010 doi:10.1093/annonc/mdq319
Abstract
Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care
T. R. Asmis, E. Powell, C. S. Karapetis, D. J. Jonker, D. Tu, M. Jeffery, N. Pavlakis, P. Gibbs, L. Zhu, D.-A. Dueck, R. Whittom, C. Langer, and C. J. O'Callaghan
Ann Oncol
(2011)22(1):118-126first published online July 5, 2010 doi:10.1093/annonc/mdq309
Abstract
